190 related articles for article (PubMed ID: 21604008)
1. Bisphosphonate prescribing, persistence and cumulative exposure in Ontario, Canada.
Burden AM; Paterson JM; Solomon DH; Mamdani M; Juurlink DN; Cadarette SM
Osteoporos Int; 2012 Mar; 23(3):1075-82. PubMed ID: 21604008
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonate and denosumab initiation in older adults in Ontario, Canada: a population-based cohort study.
Clemens KK; Jeyakumar N; Ouédraogo AM; Thain J; Khan T
Arch Osteoporos; 2020 Aug; 15(1):133. PubMed ID: 32816151
[TBL] [Abstract][Full Text] [Related]
3. Osteoporosis medication prescribing in British Columbia and Ontario: impact of public drug coverage.
Cadarette SM; Carney G; Baek D; Gunraj N; Paterson JM; Dormuth CR
Osteoporos Int; 2012 Apr; 23(4):1475-80. PubMed ID: 21901476
[TBL] [Abstract][Full Text] [Related]
4. Are long-term bisphosphonate users a reality? Dose years for current bisphosphonate users assessed using the danish national prescription database.
Abrahamsen B
Osteoporos Int; 2013 Jan; 24(1):369-72. PubMed ID: 22572963
[TBL] [Abstract][Full Text] [Related]
5. Descriptive analysis of concomitant prescription medication patterns from 1999 to 2004 among US women receiving daily or weekly oral bisphosphonate therapy.
Gold DT; Bonnick SL; Amonkar MM; Kamel HK; Agarwal S; Zaidi M
Gend Med; 2008 Dec; 5(4):374-84. PubMed ID: 19108810
[TBL] [Abstract][Full Text] [Related]
6. Denosumab utilization among older adults in Ontario: patient characteristics, persistence with therapy, and return to therapy after an extended gap.
Ban JK; Hao BB; McCarthy L; Guilcher SJT; Cadarette SM
Osteoporos Int; 2019 Sep; 30(9):1865-1872. PubMed ID: 31317248
[TBL] [Abstract][Full Text] [Related]
7. Primary non-adherence to bisphosphonates in an integrated healthcare setting.
Reynolds K; Muntner P; Cheetham TC; Harrison TN; Morisky DE; Silverman S; Gold DT; Vansomphone SS; Wei R; O'Malley CD
Osteoporos Int; 2013 Sep; 24(9):2509-17. PubMed ID: 23595561
[TBL] [Abstract][Full Text] [Related]
8. Adherence to osteoporosis medications amongst Singaporean patients.
Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
[TBL] [Abstract][Full Text] [Related]
9. Management of oral bisphosphonates treatment by rheumatologists and determinants of therapeutic changes: a case-vignette-based study.
Roux C; Baron G; Briot K; Roux B; Cortet B; Thomas T
Osteoporos Int; 2017 Dec; 28(12):3339-3345. PubMed ID: 28852785
[TBL] [Abstract][Full Text] [Related]
10. Predicting Adherence and Persistence with Oral Bisphosphonate Therapy in an Integrated Health Care Delivery System.
Hui RL; Adams AL; Niu F; Ettinger B; Yi DK; Chandra M; Lo JC
J Manag Care Spec Pharm; 2017 Apr; 23(4):503-512. PubMed ID: 28345435
[TBL] [Abstract][Full Text] [Related]
11. Adherence to osteoporosis pharmacotherapy is underestimated using days supply values in electronic pharmacy claims data.
Burden AM; Paterson JM; Gruneir A; Cadarette SM
Pharmacoepidemiol Drug Saf; 2015 Jan; 24(1):67-74. PubMed ID: 25331490
[TBL] [Abstract][Full Text] [Related]
12. Treatment patterns and long-term persistence with osteoporosis therapies in women with Medicare fee-for-service (FFS) coverage.
Singer AJ; Liu J; Yan H; Stad RK; Gandra SR; Yehoshua A
Osteoporos Int; 2021 Dec; 32(12):2473-2484. PubMed ID: 34095966
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US Military Health System.
Devine J; Trice S; Finney Z; Yarger S; Nwokeji E; Linton A; Davies W
Osteoporos Int; 2012 Apr; 23(4):1415-24. PubMed ID: 21786005
[TBL] [Abstract][Full Text] [Related]
14. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates.
Hadji P; Claus V; Ziller V; Intorcia M; Kostev K; Steinle T
Osteoporos Int; 2012 Jan; 23(1):223-31. PubMed ID: 21308365
[TBL] [Abstract][Full Text] [Related]
15. Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
Hayes KN; Ban JK; Athanasiadis G; Burden AM; Cadarette SM
Osteoporos Int; 2019 Nov; 30(11):2311-2319. PubMed ID: 31317249
[TBL] [Abstract][Full Text] [Related]
16. Predictors of oral bisphosphonate prescriptions in post-menopausal women with osteoporosis in a real-world setting in the USA.
Asche C; Nelson R; McAdam-Marx C; Jhaveri M; Ye X
Osteoporos Int; 2010 Aug; 21(8):1427-36. PubMed ID: 19798459
[TBL] [Abstract][Full Text] [Related]
17. Over half of seniors who start oral bisphosphonate therapy are exposed for 3 or more years: novel rolling window approach and patterns of use.
Hayes KN; He N; Brown KA; Cheung AM; Juurlink DN; Cadarette SM
Osteoporos Int; 2021 Jul; 32(7):1413-1420. PubMed ID: 33415374
[TBL] [Abstract][Full Text] [Related]
18. Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study.
Gonnelli S; Caffarelli C; Letizia Mauro G; Di Munno O; Malavolta N; Migliaccio S; Nuti R
Aging Clin Exp Res; 2019 Nov; 31(11):1541-1547. PubMed ID: 31030419
[TBL] [Abstract][Full Text] [Related]
19. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis.
Imaz I; Zegarra P; González-Enríquez J; Rubio B; Alcazar R; Amate JM
Osteoporos Int; 2010 Nov; 21(11):1943-51. PubMed ID: 19967338
[TBL] [Abstract][Full Text] [Related]
20. Compliance and persistence to oral bisphosphonate therapy following initiation within a secondary fracture prevention program: a randomised controlled trial of specialist vs. non-specialist management.
Ganda K; Schaffer A; Pearson S; Seibel MJ
Osteoporos Int; 2014 Apr; 25(4):1345-55. PubMed ID: 24445732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
